Wall Street analysts forecast that Sientra Inc (NASDAQ:SIEN) will announce earnings of ($0.48) per share for the current quarter, according to Zacks. Four analysts have made estimates for Sientra’s earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.60). Sientra posted earnings of ($0.72) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 33.3%. The firm is expected to announce its next earnings report on Tuesday, November 5th.
On average, analysts expect that Sientra will report full-year earnings of ($2.35) per share for the current fiscal year, with EPS estimates ranging from ($2.48) to ($2.27). For the next financial year, analysts expect that the company will report earnings of ($1.70) per share, with EPS estimates ranging from ($2.51) to ($1.36). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Sientra.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($1.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.50). Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The company had revenue of $20.53 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same quarter in the prior year, the company posted ($0.73) EPS. The company’s revenue for the quarter was up 17.0% on a year-over-year basis.
In other Sientra news, CFO Paul Sean Little bought 17,391 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were purchased at an average price of $5.75 per share, for a total transaction of $99,998.25. Following the transaction, the chief financial officer now directly owns 94,891 shares of the company’s stock, valued at approximately $545,623.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Keith J. Sullivan bought 20,869 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were acquired at an average price of $5.75 per share, for a total transaction of $119,996.75. Following the transaction, the director now directly owns 203,141 shares in the company, valued at $1,168,060.75. The disclosure for this purchase can be found here. Company insiders own 13.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of SIEN. Schroder Investment Management Group acquired a new position in Sientra in the 2nd quarter valued at $7,700,000. UBS Group AG raised its stake in Sientra by 37.9% in the 2nd quarter. UBS Group AG now owns 2,657,863 shares of the medical instruments supplier’s stock valued at $16,372,000 after purchasing an additional 730,475 shares during the last quarter. Vanguard Group Inc. raised its stake in Sientra by 64.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,857,953 shares of the medical instruments supplier’s stock valued at $11,445,000 after purchasing an additional 727,906 shares during the last quarter. Marshall Wace LLP raised its stake in Sientra by 6,998.6% in the 2nd quarter. Marshall Wace LLP now owns 710,142 shares of the medical instruments supplier’s stock valued at $4,375,000 after purchasing an additional 700,138 shares during the last quarter. Finally, Citadel Advisors LLC raised its stake in Sientra by 421.7% in the 2nd quarter. Citadel Advisors LLC now owns 450,910 shares of the medical instruments supplier’s stock valued at $2,778,000 after purchasing an additional 364,473 shares during the last quarter. 96.69% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:SIEN traded down $0.09 during midday trading on Tuesday, reaching $6.81. 447,464 shares of the company’s stock traded hands, compared to its average volume of 897,099. Sientra has a 1 year low of $4.78 and a 1 year high of $26.65. The company has a market cap of $335.67 million, a P/E ratio of -2.10 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.99 and a current ratio of 2.33. The company has a fifty day simple moving average of $5.97 and a two-hundred day simple moving average of $7.75.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.